FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease ...Middle East

Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8. STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration...

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease )

Also on site :

• ‘This is murder': Family remembers victims killed in Austin fire as 4th body recovered
• SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGMA, NVEE, SOAR, PLL on Behalf of Shareholders
• Ilona Maher Gets Invite to Dance With Coco Gauff and Aryna Sabalenka